There is a new era for anticoagulant therapy in Central and Eastern Europe. Today, Pradaxa® is the single new oral anticoagulant to have a specific reversal agent Praxbind®
- Authors: - -
- Issue: Vol 18, No 1 (2016)
- Pages: 8-9
- Section: Articles
- URL: https://journals.rcsi.science/2075-1753/article/view/94351
- ID: 94351
Cite item
Full Text
Abstract
После регистрации препарата Праксбайнд® (идаруцизумаб*) рядом регулирующих органов в мире у врачей и пациентов в Европе, в том числе в странах Центральной и Восточной Европы, в антикоагулянтной терапии начался следующий этап.
Full Text
##article.viewOnOriginalSite##References
- Boehringer Ingelheim data on file.
- PRAXBINDR EMA Prescribing Information, 2015.
- Pollack C.V et al. Idarucizumab for Dabigatran Reversal. NEJM 2015; 373: 511-20.
- Glund S et al. Safety, tolerability, and efficacy of idarucizumab for the reversal of the anticoagulant effect of dabigatran in healthy male volunteers: a randomised, placebo - controlled, double - blind phase 1 trial. Lancet 2015; 386: 680-90.
- Glund S et al. Idarucizumab, a Specific Antidote for Dabigatran: Immediate, Complete and Sustained Reversal of Dabigatran Induced Anticoagulation in Elderly and Renally Impaired Subjects. Oral presentation on 8 December 2014 at The 56th American Society of Hematology Annual Meeting & Exposition, San Francisco, USA. Blood 2014; 124: Abstract 344.
- Glund S et al. A randomised study in healthy volunteers to investigate the safety, tolerability and pharmacokinetics of idarucizumab, a specific antidote to dabigatran. Thromb Haemost 2015; 113: 943-51.
- Schiele F et al. A specific antidote for dabigatran: functional and structural characterization. Blood 2013; 121: 3554-62.
- Pollack C.V et al. Design and rationale for RE-VERSE AD: A phase 3 study of idarucizumab, a specific reversal agent for dabigatran. Thromb Haemost 2015; 114: 198-205.
